LYKALABS

** Shares of Lyka Labs Ltd LYKA.NS rise as much as 7.1% to 160 rupees

** The pharma co says the Central Drugs Standard Control Organization of India (CDSCO) gave permission to Lyka Labs to manufacture and market Pregabalin Gel 8% w/w for treatment of diabetic neuropathic pain in India

** Stock on track to gain for a third straight day

** More than 200,000 shares traded, their busiest day yet in a week

** LYKA stock up 6.3%, adds to YTD gains of 28.2% so far

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Oct 14 (Reuters) - Lyka Labs Ltd LYKA.NS:

• GOT PERMISSION FROM CDSCO TO MANUFACTURE, MARKET PREGABALIN GEL 8% W/W IN INDIA

Source text for Eikon: ID:nBSE90WB6p

Further company coverage: LYKA.NS

(([email protected];;))

Oct 11 (Reuters) - Lyka Labs Ltd LYKA.NS:

• APPROVED FILING OF FRESH APPLICATION OF SCHEME OF AMALGAMATION OF LYKA EXPORTS WITH CO

Source text for Eikon: ID:nBSE6r9DlH

Further company coverage: LYKA.NS

(([email protected];;))

Sept 25 (Reuters) - Lyka Labs Ltd LYKA.NS:

• NCLT REJECTS PETITION FOR AMALGAMATION OF UNIT LYKA EXPORTS WITH CO

Source text for Eikon: ID:nBSE1yK1Cx

Further company coverage: LYKA.NS

(([email protected];;))

Jan 16 (Reuters) - Lyka Labs Ltd LYKA.NS:

• RE-APPOINTED KUNAL GANDHI AS MANAGING DIRECTOR

Further company coverage: LYKA.NS

(([email protected];))

** Shares of drugmaker Lyka Labs LYKA.NS rise as much as 6.2% to 125.75 rupees

** Co receives product permission from India's drug regulatory body to manufacture and market Tofacitinib Ointment 2% w/w

** Says, permission awarded after co completed clinical trial on 125 patients across 8 clinical trial centres within India

** Share price above 50-day, 100-day and 200-day simple moving averages, suggesting bullish trend

** More than 248,000 shares change hands by 11:43 a.m. IST, almost double the 30-day avg

** Including day's gains, stock down 4.4% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

May 23 (Reuters) - Lyka Labs Ltd LYKA.NS:

• MARCH-QUARTER CONSOL NET LOSS AFTER TAX 30.1 MILLION RUPEES VERSUS LOSS 150.7 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 222.4 MILLION RUPEES VERSUS 351.9 MILLION RUPEES

Source text for Eikon: ID:nBSE7ydDLy

Further company coverage: LYKA.NS

(([email protected];))

April 18 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• LYKA LABS LTD - CONSIDERED ISSUE OF 2.4 MILLION SHARES UPON CONVERSION OF WARRANTS TO IPCA LABORATORIES

Source text for Eikon: ID:nBSE2W4l8J

Further company coverage: IPCA.NS

(([email protected];))